THREE PHASE 1/2, OPEN‐LABEL STUDIES OF CEREBLON E3 LIGASE MODULATOR (CELMOD)‐BASED REGIMENS IN NEWLY DIAGNOSED (ND) OR RELAPSED/REFRACTORY (R/R) NON‐HODGKIN LYMPHOMA (NHL). (17th June 2021) - Morschhauser, F.; Nowakowski, G. S.; Cartron, G.; Kesanakurthy, V.; Gkasiamis, A.; Patah, P.; Delarue, R.; Wang, T.; Li, J.; Xian, D.; Fox, C. P.; Martin, P.